Anavex Life Sciences Q3 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Cash And Equivalents Of $138.8M
Portfolio Pulse from Benzinga Newsdesk
Anavex Life Sciences (NASDAQ:AVXL) reported a Q3 2024 GAAP EPS of $(0.14), beating the analyst consensus estimate of $(0.16) by 12.5%. The company's cash and equivalents stand at $138.8 million.
August 06, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anavex Life Sciences reported a Q3 2024 GAAP EPS of $(0.14), beating the analyst consensus estimate of $(0.16) by 12.5%. The company's cash and equivalents stand at $138.8 million.
Beating EPS estimates is generally a positive indicator for a company's stock price. The unchanged EPS from the same period last year suggests stability, and the substantial cash reserves of $138.8 million provide a strong financial cushion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100